High Court Sanctions Verona Pharma Acquisition by MSD
In a significant development, Verona Pharma plc (NASDAQ: VRNA), a biopharmaceutical leader in respiratory disease treatment, recently confirmed that the High Court of Justice of England and Wales has delivered its approval for MSD's acquisition. This strategic move is set to enhance the scope and reach of innovative therapies addressing chronic respiratory diseases.
Details of the Acquisition
The agreement for MSD to acquire Verona Pharma stands at an impressive value of approximately $10 billion, with MSD planning to pay $107 per American Depository Share (ADS). Each ADS represents eight ordinary shares of Verona Pharma.
The Approval Process
This acquisition is being executed through a Court-sanctioned scheme of arrangement under English law. Verona Pharma has expressed its satisfaction with the Court's decision, which paves the way for the transaction's finalization.
Expected Timeline for Closing
The closing of this transaction is anticipated to take place soon, with the Scheme becoming effective once the Court Order is delivered to the Registrar of Companies. As communicated previously, this delivery is expected to occur shortly, allowing the operational aspects of Verona Pharma to transition under MSD's ownership.
Last Day of Trading
Investors should note that the last day for trading Verona ADSs on the Nasdaq is expected to be the day just before the execution of the deal, coinciding with the effective date.
Implications for Shareholders
In light of this acquisition, Verona Pharma's shareholders are encouraged to familiarize themselves with any legal requirements as the transaction progresses. Shareholders outside of the primary jurisdiction must ensure compliance with local laws and may benefit from consulting legal advisers regarding their specific situations.
The Future of Verona Pharma
Post-acquisition, Verona Pharma will continue to focus on developing innovative therapies targeted at chronic respiratory diseases, helping to address significant unmet medical needs. MSD's extensive resources and market reach are expected to bolster Verona’s initiatives, enhancing the development and commercialization of their therapies.
Contact Information
For any inquiries related to this acquisition, stakeholders can reach out to Verona Pharma's investor relations team. Below are the contact details:
Investor Relations and Media Inquiries
Verona Pharma plc
Tel: +1-844-341-9901
Contact: Victoria Stewart, Senior Director of Investor Relations and Communications
Email: IR@veronapharma.com
For US Investor inquiries, contact Argot Partners at +1-212-600-1902 or email verona@argotpartners.com.
Frequently Asked Questions
What was the main outcome of the High Court's decision?
The court approved MSD's acquisition of Verona Pharma, enabling the transaction to proceed.
What is the transaction value for the acquisition?
The acquisition of Verona Pharma by MSD has an approximate total value of $10 billion.
When will the transaction officially close?
The transaction closing is expected to take effect once the court's decision is delivered to the Registrar of Companies.
What implications does this have for shareholders?
Shareholders must comply with legal requirements and are urged to seek advice on their obligations during this process.
How will MSD's acquisition benefit Verona Pharma?
MSD's resources and market presence are expected to significantly enhance Verona's capabilities in developing and commercializing therapies for respiratory diseases.
